Medicines planning
47 results
Applied filters
Have your say: biosimilars and patents resources
20 May 2026We are reviewing Specialist Pharmacy Service (SPS) resources on biosimilars and patents to ensure they meet the needs of NHS services.
Biosimilar and key generic medicines – June 2026 update
25 June 2026An update about biosimilar and key generic medicines to support system planning and mobilisation
The licence and supporting evidence for denosumab 120mg biosimilars
16 January 2026Denosumab 120mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for golimumab biosimilar
2 June 2026We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
The licence and supporting evidence for denosumab 60mg biosimilars
24 April 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use ranibizumab biosimilar
5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Annual medicines planning publication, Prescribing Outlook
12 January 2026Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
Primary care discussions: biosimilar insulin
30 September 2025Discussion about the considerations of implementing biosimilar insulin in primary care. Hints and tips for systems considering a move to biosimilar insulin.
The licence and supporting evidence for aflibercept biosimilars
4 February 2026Aflibercept 2mg biosimilars are available for NHS use. Learn about supporting evidence and differences.